Kobayashi et al published another larger study involving 109 de novo CD5+ DLBCL casesprimarily studying their clinical characteristics.19 These cases were compared with 384 CD5− DLBCL and 128 cyclin D1–positive MCLcases. The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.